Furthermore, ROCKi+anti-PD-1 decreased levels of PD-1 ligand (CD274, best known as PD-L1) in both tumor cells and CD206+ macrophages (Figure 1), which could contribute to enhanced anti-PD-1 efficacy. Here, MRC1 is linked to neoplasm.